Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: A Cancer and Leukemia Group B study

Gerard Lozanski, Amy S. Ruppert, Nyla A. Heerema, Arletta Lozanski, David M. Lucas, Amber Gordon, John G. Gribben, Vicki A. Morrison, Kanti M. Rai, Guido Marcucci, Richard A. Larson, John C. Byrd

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

The impact of mutation of the ATM (ataxia telangiectasia mutated) gene in chronic lymphocytic leukemia (CLL) treatment outcome has not been examined. We studied ATM mutations in 73 patients treated with fludarabine and rituximab. ATM gene mutation analysis was performed using temperature gradient capillary electrophoresis. The impact of detected variants on overall survival (OS) and progression-free survival (PFS) was tested with proportional hazards models. None of the 73 patients demonstrated truncating ATM mutations; 17 (23%, 95% confidence interval 14-35%) had non-silent variants (ATM-NSVs), including 13 known ATM polymorphisms and four missense variants. ATM-NSVs were not significantly associated with any baseline characteristics including immunoglobulin heavy chain variable gene (IGVH) status. In multivariable models, no significant differences in complete response (p = 0.70), PFS (p = 0.59) or OS (p = 0.13) were observed. Our data indicate that truncating ATM mutations are rare in patients with CLL. Furthermore, in this dataset, these non-silent variants had limited impact on PFS and OS.

Original languageEnglish (US)
Pages (from-to)1743-1748
Number of pages6
JournalLeukemia and Lymphoma
Volume53
Issue number9
DOIs
StatePublished - Sep 2012

Keywords

  • ATM mutation
  • Chronic lymphocytic leukemia
  • chemoimmunotherapy
  • prognosis

Fingerprint Dive into the research topics of 'Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: A Cancer and Leukemia Group B study'. Together they form a unique fingerprint.

Cite this